Document:

Exhibit 10.16

                      OEM SUPPLY AND DISTRIBUTION AGREEMENT

         THIS AGREEMENT ("Agreement") is made this 21st day of May, 2003, by and
between Specialized Health Products International, Inc., a Delaware corporation
having an address at 585 West 500 South, Bountiful, Utah 84010 (hereinafter
referred to as "SHPI"), and ExelInt International, Company, a California
corporation having a place of business at 5840 West Centinela Ave., Los Angeles,
California 90045 (hereinafter referred to as "EXEL").

                                    RECITALS

         WHEREAS, SHPI desires to grant to EXEL, and EXEL desires to accept from
SHPI, the non-exclusive right to promote, market, distribute and sell the
"Products" (as hereinafter defined) and all "Improvements" (as hereinafter
defined) in the "Field" (as hereinafter defined) throughout the "Territory" (as
hereinafter defined).

         NOW, THEREFORE, in consideration of the terms and conditions set forth
in this Agreement and for other good and valuable consideration, the receipt and
sufficiency of which is acknowledged by the execution hereof, SHPI and EXEL
hereby agree as follows:

                                 I. DEFINITIONS

         The following terms are defined for purposes of this Agreement.

         1.1. "Effective Date" shall mean the date and year first written above.

         1.2. "Affiliate" shall mean any person or corporation or other business
entity controlled by, controlling, or under common control with a party to this
Agreement.

         1.3. "Act" shall mean the United States Food, Drug and Cosmetic Act of
1938, as amended and all regulations promulgated pursuant thereto, and any state
and local laws and regulations thereunder promulgated and all similar laws and
regulations of any other country or relevant jurisdiction related to the
development, manufacture, sale or distribution of Products or Improvements.

         1.4. "Products" shall mean single-pack, E-beam sterilized safety port
access infusion sets (commonly referred to as Huber needle infusion sets), which
are manufactured by SHPI.

         1.5. "Improvements" shall mean any modification, enhancement, further
development and/or improvement to the Products, made or acquired at any time
during the term of this Agreement by SHPI, or any Affiliate of SHPI.

         1.6. "Specifications" shall mean the raw material, manufacturing,
quality assurance, packaging and finished product specifications and protocols
relating to the Products previously provided, or in the case of Improvements, as
will be provided, by SHPI to EXEL, as the same may be modified and/or
supplemented pursuant to the provisions hereof.

         1.7. "Field" shall mean hospitals and group purchasing organizations
(GPOs) and alternate sites, such as homecare services, nursing homes, oncology
centers, infusion centers, same day surgery centers, physician offices and
clinics, non-hospital pharmacies and pain clinics.

         1.8. "Territory" shall mean the United States. The Territory shall
extend to the United Kingdom and Japan when SHPI obtains regulatory clearance in
the United Kingdom and Japan respectively.

<PAGE>

         1.9. "Confidential Information" shall mean any information of a
confidential and/or proprietary nature as to which EXEL or an Affiliate of EXEL
or SHPI or an Affiliate of SHPI, as the disclosing party, prior to or during the
term of this Agreement, develops or acquires any interest, including but not
limited to, all discoveries, inventions, improvements, and ideas relating to any
process, formula, machine, device, manufacture, composition of matter, plan or
design, whether patentable or not, or relating to the conduct of business by the
disclosing party (including the existence and subject matter of this Agreement)
which, prior to or during the term of this Agreement, was or is disclosed to the
other party, as the receiving party, exclusive of data or information: (i)
which, at the time of disclosure hereunder, was in the public domain or which,
subsequent to disclosure hereunder, becomes part of the public domain by any
means other than the breach by the receiving party of its obligations hereunder,
or (ii) which was known to the receiving party, at the time of disclosure
hereunder, as evidenced by the receiving party's business records maintained in
the ordinary course of business, or (iii) which is, at any time, disclosed to
the receiving party by any person or entity not a party hereto whom the
receiving party believes, after reasonable inquiry, has the right to disclose
the same, or (iv) which is developed by an employee of the receiving party who
is shown, by competent proof and by clear and convincing evidence, not to have
been privy to information disclosed by the disclosing party, or (v) which is
disclosed verbally, except where the disclosing party reduces the verbal
disclosure to writing, marks the same as confidential and proprietary and
furnishes the receiving party with the reduction to writing within thirty (30)
days of the verbal disclosure.

         1.10. "Contract Year" shall mean the twelve-month period commencing on
the date of the first Commercial Sale, and each successive twelve-month period
thereafter.

         1.11. "Regulatory Approval" shall mean the notification to or
concurrence, acknowledgment, or approval of any governmental or
quasi-governmental agency or regulatory body, which notification, concurrence,
acknowledgment or approval is necessary for or useful to the manufacturing,
processing, marketing or sale of Products or Improvements anywhere in the United
States, and which is made in the name of SHPI or has been given/granted on
behalf of SHPI.

         1.15. "Commercial Sale" - means, with respect to the Products, or any
Improvement which EXEL elects to distribute hereunder, the sale by EXEL or any
Affiliate of EXEL (or their respective distributors) to any non-Affiliate.

                       II. REPRESENTATIONS AND WARRANTIES

         2.1. SHPI Representations and Warranties. SHPI hereby represents and
warrants to EXEL:

                  (a) that it has received pre-market notification, as defined
         in section 510(k) of the Act, with respect to all Products and that it
         will manufacture the Products under such pre-market notifications, and

                   (b) that SHPI is not currently a party to any agreement, oral
         or written, which would, in any manner, be inconsistent with the rights
         herein granted to EXEL, and shall not enter into any such agreement or
         understanding, oral or written, during the term of this Agreement, nor,
         during the term of this Agreement, directly or indirectly, will engage
         in any activity which would, in any manner, be inconsistent with the
         rights herein granted to EXEL,

                  (c) that SHPI is a corporation organized, validly existing and
         in good standing under the laws of Delaware, has all requisite
         corporate power and authority to own and operate its property and to
         carry on its business as now being conducted and is duly qualified and
         in good standing to do business in any of those jurisdictions where it
         is required to be qualified, and

                  (d) that the execution and delivery of this Agreement by SHPI
         has been duly and validly authorized by all necessary corporate action
         on the part of SHPI and that (assuming valid execution by EXEL where
         applicable and subject to federal bankruptcy law) this Agreement is a
         valid and binding obligation of SHPI enforceable against it, and

                   (e) all Products may be lawfully sold in the Territory under
         the appropriate Regulatory Approvals when received by SHPI.

         2.2. EXEL Representations and Warranties. EXEL hereby represents and
warrants to SHPI:

                  (a) that EXEL is a corporation organized, validly existing and
         in good standing under the laws of California, has all requisite
         corporate power and authority to own and operate its property and to
         carry on its business as now being conducted and is duly qualified and
         in good standing to do business in any of those jurisdictions where it
         is required to be qualified as a result of ownership of property or
         residence of any of its employees or agents, and

                  (b) that the execution and delivery of this Agreement by EXEL
         has been duly and validly authorized by all necessary corporate action
         on the part of EXEL and that (assuming valid execution by SHPI and
         subject to federal bankruptcy law) this Agreement is a valid and
         binding obligation of EXEL enforceable against it, and

                  (c) that EXEL is not currently a party to any agreement or
         understanding, oral or written, which would, in any manner, be
         inconsistent with its obligations described herein and shall not enter
         into any such agreement or understanding, oral or written, during the
         term of this Agreement, nor, during the term of this Agreement,
         directly or indirectly, engage in any activity which would, in any
         manner, be inconsistent with its obligations described herein, and

                  (d) that it is registered with the Food and Drug
         Administration and authorized to sell the Products.

<PAGE>

                          III. DISTRIBUTION OF PRODUCTS

         3.1. Appointment of EXEL as Distributor. Subject to the terms and
conditions hereof, SHPI hereby appoints EXEL, and EXEL hereby agrees to act, as
a non-exclusive distributor of Products and Improvements in the Field throughout
the Territory, for the term of this Agreement. **

         3.2. EXEL's Responsibilities. EXEL will use reasonable efforts to
promote sales and use of the Products and Improvements in the Territory. SHPI
hereby expressly acknowledges and agrees that the grant set forth in Section 3.1
shall be deemed to include a grant to EXEL of the right to sell through any
Affiliate of EXEL and through distributors of EXEL or any Affiliate of EXEL.

         3.3. Device Complaints. EXEL shall maintain a system of product
complaint recording and reporting wherein it will record the details of product
complaints it receives. EXEL agrees to send copies of the complaint reports
relating to substantial design, technical or quality issues to SHPI. SHPI shall
be responsible for supporting EXEL's investigation of such complaint reports.
SHPI shall, within thirty (30) days after SHPI receives the initial complaint
reports from EXEL, forward the findings of any investigations to EXEL.

         3.4. Recall. If EXEL or SHPI are required by any competent governmental
authority to conduct a recall of any of the Products or either party determines
in its reasonable business judgment a voluntary recall of any Product is
required (and in the instance of a voluntary recall with the consent of the
other party hereto, which neither SHPI nor EXEL will unreasonably withhold),
then SHPI shall bear the reasonable expenses related to the cost and return of
the Products.

         3.5 Trademarks. Products shall be provided to EXEL on a private label
basis with SHPI's LiftLoc(R) trademark. SHPI agrees to limit usage of the
LiftLoc(R) trademark to safety infusion sets. EXEL shall be required to use the
SHPI's registered trademarks for LiftLoc(R), which include U.S. Registration
Nos. 2,681,832 and 2,678,961 respectively ("Trademarks"), in connection with the
marketing, promotion and sale of the Products and Improvements, if any, in the
Territory as approved by SHPI, which approval shall not be unreasonably
withheld. In connection with such use, SHPI hereby grants to EXEL, to the extent
necessary, a royalty-free, non-exclusive license to use and employ the
Trademarks for the term of this Agreement to affix the Trademarks to the
Products and Improvements, if any. Trademarks shall also include all common law
trademark rights to LiftLoc.

                         IV. TERMS OF PURCHASE AND SALE

         4.1. Purchase Orders. EXEL shall provide a non-binding, rolling 12
month forecast at the beginning of each calendar quarter. All sales and
purchases of Products or Improvements shall be initiated pursuant to EXEL's
purchase order for the same placed with SHPI. All such sales and purchases shall
be governed by the terms and

-----------------
The "**" marks the location of information that has been omitted and filed
separately with the Securities and Exchange Commission pursuant to a request for
confidential treatment.

<PAGE>

provisions of this Agreement and any such purchase order, provided that in the
event there is a conflict between the terms of this Agreement and any of the
terms of such purchase order, the terms of this Agreement shall prevail. All
purchase orders issued by EXEL hereunder shall be firm and non-cancelable, and
shall be submitted at least 45 days prior to the delivery date.

         4.2. Selling Price. (a) SHPI and EXEL hereby agree that: (i) the
selling prices by SHPI to EXEL for each unit of Product and any Improvement
shall be for each unit Product or any such Improvement, as the case may be, in
fully-finished, packaged and sterilized form in accordance with applicable
Specifications, (ii) the initial selling prices by SHPI to EXEL of each unit of
Product shall be as set forth on Exhibit A, which is attached hereto and
incorporated herein, which selling prices shall be firm for purchase orders
placed through the end of the fifth complete Contract Year, (iii) upon renewal
of this Agreement the selling prices by SHPI to EXEL shall be mutually agreed
upon by SHPI and EXEL, (iv) in the event EXEL desires to market any Improvement,
the initial selling prices by SHPI to EXEL for each unit of such Improvement
shall be promptly negotiated by the parties in good faith and shall be firm for
purchase orders placed thereon through the end of the period commencing on the
date of the first Commercial Sale of such Improvement and ending on the second
anniversary of such date. All payments shall be made in United States dollars.

         4.3. Delivery. (a) SHPI shall use commercially reasonable efforts to
manufacture and deliver Products to EXEL, but in no event will SHPI be obligated
to deliver more than 20% over the forecasted volumes for a quarter, as such
forecast is determined in accordance with Section 4.1. EXEL shall provide up to
six (6) months notice for increases to the forecast if the increase in volume is
more than 20% of the amount forecasted.

         4.4. Payment and Shipment. Shipment shall be in accordance with EXEL's
instructions. SHPI shall invoice EXEL for Products and Improvements at the time
of shipment. All payments shall be due net thirty (30) days after shipment. A
**% prompt payment discount may be taken on invoices paid within 20 days (**%,
20 days or net 45 days). Invoices paid after 45 days will be billed with
interest at a rate of **% per month. All shipments shall be C.I.F. (container
insurance and freight) to EXEL's Los Angeles, California distribution center.

         4.5 Minimum Purchase Requirements. (a) During each Contract Year during
the term of this Agreement (or, in the case of the first Contract Year,
including the period beginning from the Effective Date through the date of the
first Commercial Sale), EXEL agrees to place purchase orders with SHPI for a
quantity of Products and/or Improvements not less than the quantity applicable
to such Contract Year, as set forth in Exhibit A, which is attached hereto and
incorporated herein (hereinafter referred to as the "Minimum Purchase
Requirements").

         4.6 Competitive Products. The parties agree that nothing in this
Agreement shall restrict SHPI's right to manufacture, market and sell and/or
license, or EXEL's right to distribute, products or technologies competitive
with the Products.

--------------------
The "**" marks the location of information that has been omitted and filed
separately with the Securities and Exchange Commission pursuant to a request for
confidential treatment.

<PAGE>

                           V. MANUFACTURE OF PRODUCTS

         5.1. SHPI hereby represents and warrants to EXEL:

                  (a) that each of the Products and Improvements sold to EXEL
         hereunder shall be manufactured in accordance with the requirements of
         the Quality Systems Regulations set forth in 21CFR, Parts 808, 812 and
         820; and

                  (b) that each of the Products and Improvements sold to EXEL
         hereunder shall be new, free from defects in material and workmanship,
         and shall comply in all respects with the applicable Specifications
         therefor; and

                  (c) that each of the Products and Improvements sold to EXEL
         hereunder will not, at the time of delivery to EXEL, be adulterated or
         misbranded within the meaning of the Act or within the meaning of any
         jurisdiction in which the definitions of misbranding and adulterating
         are substantially the same as in the Act, nor, following FDA approval
         of Products and Improvements, will any Product or Improvement at the
         time of delivery to EXEL be an article which may not, under the Act, be
         introduced into interstate commerce, and

                  (d) that SHPI holds good and marketable title to all Products
         or Improvements and they shall comply with their intended use, and

                  (e) that all Products and Improvements shall, at the time of
         delivery to EXEL, have an expiration date of not less than 24 months
         from the date of manufacture and shall have a remaining shelf-life of
         at least 22 months. SHPI will complete required testing and
         documentation to support 36-month expiration dates by September 31,
         2003. However, there can be no assurances such testing will be
         successful.

         5.2. There are no other express or implied warranties, including any
warranty of merchantability or fitness for a particular purpose. In the event of
any breach of the warranties set forth in Section 5.1 hereof, SHPI shall, at
SHPI's sole cost and expense, at EXEL's option, repair or replace the Products
or Improvements which are non-conforming or defective within thirty (30) days of
the return of such item(s) to SHPI or shall credit EXEL's account for the
purchase price paid for such item(s) by EXEL upon the return thereof by EXEL.
All shipping costs incurred incident to any such breach shall be borne by SHPI.

         5.3. Labeling. Product labeling shall have primary and secondary bar
coding in compliance with the Health Industry Bar Coding standards. No changes
may be made to any Product labeling or packaging without the prior written
consent of EXEL.

<PAGE>

                            VI. TERM AND TERMINATION

         6.1. Term. (a) This Agreement shall remain in full force and effect
through the completion of the fifth Contract Year (the "Initial Term").
Thereafter, this Agreement shall be automatically renewed for successive
five-year terms unless terminated by either Party by providing written notice to
the other Party not less than ** prior the expiration of the initial term or any
renewal term. In the event this Agreement is automatically renewed, the parties
shall meet, no later than 90 days prior to the completion of the Initial Term or
any renewal term, to discuss the Minimum Purchase Requirements and Product
pricing for such renewal term.

         6.2. Breach. Except as otherwise provided in this Agreement, in the
event of a material breach or default by either of the parties hereto of any
term or provision of this Agreement on their respective parts to be observed or
performed, the party who is not in breach or default shall have the right to
give the other party notice thereof, whereupon the party receiving such notice
shall have thirty (30) days to cure or cause the cure of such breach or default,
or if the same cannot reasonably be cured within such thirty (30) days, the
party receiving such notice shall, within said period, commence or have caused
the commencement of such cure and thereafter continue to diligently prosecute or
cause the prosecution of cure of the same. If such breach or default is so
cured, this Agreement shall remain in full force and effect. If such breach or
default is not so cured, this Agreement shall immediately terminate upon notice
of termination given to the party which failed to so cure such breach or
default.

         6.3. Effect of Termination or Expiration. Expiration or prior
termination of this Agreement, for any reason, will not release either party
from any liability which at said time it has already incurred to the other
party, nor affect in any way the survival of any rights, duties or obligations
of either party which are expressly stated elsewhere in this Agreement to
survive said expiration or prior termination. Nothing in the immediately
preceding sentence will affect, be construed or operate as a waiver of the right
of the party aggrieved by any breach of this Agreement to be compensated for any
injury or damage resulting therefrom which is incurred before or after such
expiration or termination.

         6.4. Disposition of Inventory. In the event of termination or
expiration of this Agreement for any reason, EXEL will retain its inventory and
stock of the Products or Improvements, if any, that has been paid for by EXEL.
EXEL will be entitled to sell its stock of the Products or Improvements, if any,
for a twenty-four month period following the termination or expiration of this
Agreement, or if such date is later, the date of delivery of any Products or
Improvements to EXEL.

                             VII. REGULATORY MATTERS

         7.1. SHPI agrees to fully comply in all respects with the Act. SHPI
agrees to provide EXEL with copies of all papers, concurrence and office actions
pertaining to regulatory communications.

-------------------
The "**" marks the location of information that has been omitted and filed
separately with the Securities and Exchange Commission pursuant to a request for
confidential treatment.

<PAGE>

         7.2. SHPI represents and covenants that all Products and Improvements,
if any, shall have all Regulatory Approvals in compliance with the Act necessary
for SHPI to manufacture and for EXEL to market and sell the Products and
Improvements. Same shall have been validly issued and shall be in full force and
effect.

         7.3  SHPI and EXEL will mutually agree on a product complaint protocol.

                        VIII. INDEMNIFICATION/INSURANCE.

         SHPI shall obtain an endorsement from its product liability insurer to
protect EXEL from any liability which arises or results from alleged injury
incident to the use of any products covered by this Agreement up to ** per
occurrence and ** in aggregate. SHPI further agrees to indemnify and hold
harmless EXEL from any claims, lawsuits, losses, liabilities and damages of any
nature arising out of any patent infringement or product liability or any other
claim relating to a defect of a product, except with respect to claims based
solely upon EXEL' misrepresentations regarding the products. As a condition
precedent to SHPI obligations under this clause, the party charged in such suit
shall promptly notify SHPI and shall not settle the same without SHPI's prior
written approval. EXEL shall indemnify SHPI against all suits, actions, claims,
demands, judgments, liabilities and expenses relating to the sale and/or
distribution of any products covered by this Agreement.

                                IX. MISCELLANEOUS

         9.1. Confidential Information. Each party shall hold in confidence any
Confidential Information disclosed by the other or otherwise obtained by such
party as a result of activities contemplated by this Agreement, and each party
shall protect the confidentiality thereof with the same degree of care that it
exercises with respect to its own information of a like nature, but in no event
less than reasonable care. Access to Confidential Information must be restricted
to the receiving party's employees, who, in each case, need to have access to
carry out a permitted use and are bound in writing to maintain the
confidentiality of such Confidential Information. The Confidential Information
and all copies of part or all thereof, shall be and remain the exclusive
property of the disclosing party, and the receiving party shall acquire only
such rights as are expressly set forth under the terms and conditions of this
Agreement and only for so long as such rights are in effect.

         9.2. Survival. The following Articles or Sections shall continue in
effect notwithstanding any termination of this Agreement: Article II, Article V,
Section 6.3, Section 6.4, Article VII, Section 8.1, Section 9.1, Section 9.5,
Section 9.7 and Article X, and no termination of this Agreement shall relieve
any party of liability for a breach or violation of this Agreement occurring
before such termination.

         9.3. No Agency. This Agreement shall not constitute EXEL the agent or
legal representative of SHPI for any purpose whatsoever and EXEL shall not hold
itself out as an agent of SHPI. This Agreement creates no relationship of joint
ventures, partners, associates, employment or principal and agent between the
parties, and

--------------------
The "**" marks the location of information that has been omitted and filed
separately with the Securities and Exchange Commission pursuant to a request for
confidential treatment.

<PAGE>

both parties are acting as independent contractors. EXEL is not granted herein
any right or authority to and shall not attempt to assume or create any
obligation or responsibility for or on behalf of SHPI. EXEL shall not have any
authority to bind SHPI to any contract, whether of employment or otherwise, and
EXEL shall bear all of its own expenses for its operations, including, without
limitation, the compensation of its employees and salespeople and the
maintenance of its offices, service and warehouse facilities. EXEL shall be
solely responsible for its own employees and salespeople and for their acts and
the things done by them.

         9.4. Amendments. This Agreement may be amended, modified or
supplemented only by a written instrument executed by the parties hereto.

         9.5. Waivers. No waiver of any provision of this Agreement, or consent
to any departure from the terms hereof, shall be effective unless the same shall
be in writing and signed by the party waiving or consenting thereto. No failure
on the part of any party to exercise and no delay in exercising, any right or
remedy hereunder shall operate as a waiver thereof, nor shall any single or
partial exercise of any such right or remedy by such party preclude any other or
further exercise thereof or the exercise of any other right or remedy. The
waiver by any party hereto of a breach of any provision of this Agreement shall
not operate as a waiver of any subsequent breach. All rights and remedies
hereunder are cumulative and are in addition to and not exclusive of any other
rights and remedies provided by law.

         9.6. Performance. Each party hereto acknowledges that money damages
alone will not adequately compensate such party for breach of such party's
obligations under Section 10.1 and, therefore, agrees that in the event of the
breach or threatened breach of any such obligation, in addition to all other
remedies available to the other party, at law, in equity or otherwise, such
other party shall be entitled to injunctive relief compelling specific
performance of, or other compliance with, the terms of such Section.

         9.7. Notices. Any notice or communication given pursuant to this
Agreement by any party to any other party shall be in writing and shall be
sufficiently given if personally delivered, sent by facsimile or other means of
confirmed electronic transmission or sent by a recognized next-day courier
service or by mail, postage prepaid to the parties at the following addresses or
to such other address as either party may hereafter designate to the others by
like notice:

                  (a) if to SHPI, to:

                           Specialized Health Products International, Inc.
                           585 West 500 South
                           Bountiful, Utah 84010
                           Attention: General Counsel
                           Facsimile Number: (801) 298-1759

                  (b) if to EXEL, to:

                           ExelInt International, Company
                           5840 West Centinela Ave.
                           Los Angeles, California 90045
                           Attention:  President
                           Facsimile Number: (310) 649-1178

         9.8. Expenses. Each party hereto shall pay its own expenses in
connection with the transactions contemplated hereby, whether or not they are
completed.

         9.9. Publicity. All notices to third parties and all other publicity
relating to the transactions contemplated by this Agreement shall be jointly
planned, coordinated and agreed to by the parties except to the extent
disclosures are required by law.

         9.10. Entire Agreement. This Agreement constitutes the entire agreement
among the parties hereto with respect to the subject matter hereof and
supersedes all negotiations, representations, warranties, commitments, offers,
contracts and writings prior to the date hereof.

         9.11. Governing Law. This Agreement shall be governed by and construed
and enforced in accordance with, the substantive laws of the state of Utah,
without giving effect to its conflicts of law rules.

         9.12. Severability. Any provision of this Agreement which is prohibited
or unenforceable in any jurisdiction shall, as to such jurisdiction, be
ineffective to the extent of such prohibition or unenforceability without
invalidating the remaining provisions hereof or affecting the validity or
enforceability of such provision in any other jurisdiction. In the event that
any provision of this Agreement shall be determined to be unenforceable by
reason of its extension for too great a period of time or over too large a
geographic area or over too great a range of activities, it shall be interpreted
to extend only over the maximum period of time, geographic area or range of
activities as to which it may be enforceable.

         9.13. Exhibits. All Exhibits mentioned in this Agreement shall be
attached to this Agreement and shall form an integral part hereof. All
capitalized terms defined in this Agreement which are used in any Exhibit shall,
unless the context otherwise requires, have the same meaning therein as given
herein.

         9.14. Counterparts. This Agreement may be executed in two (2) or more
counterparts, including facsimile counterparts, all of which shall be considered
one and the same agreement and shall become effective when two (2) or more
counterparts have been signed by each of the parties and delivered to the other
parties, it being understood that all parties need not sign the same
counterpart.

         9.15. Assignments; Successors and Assigns. Neither party shall transfer
or assign (by operation of law or otherwise) its rights or obligations under
this Agreement without the prior written consent of the other party. Subject to
the preceding sentence, this Agreement shall be binding upon and inure to the
benefit of each of the parties hereto and their permitted successors and
assigns.

         9.16. Force Majeure. Either party shall be excused from delay in
performing or from its failure to perform hereunder to the extent that such
delay or failure results from any cause or causes beyond such party's reasonable
control, including: delay by any supplier in providing materials, parts or
services; delay by any carrier; fire; flood; acts of God; labor dispute; riot;
compliance with any applicable governmental act, regulation or request; and
shortage of labor, materials or manufacturing facilities.

         9.17. Captions. The Article and Section headings contained in this
Agreement have been inserted for convenience of reference only and are not and
shall not be deemed or construed as constituting a part of this Agreement.

                                 X. ARBITRATION

         10.1. In the event of a dispute of whatever nature arising between the
parties, including but not limited to, those arising out of or relating to this
Agreement or the construction, interpretation, performance, breach, termination,
enforceability or validity of this Agreement, the parties shall exercise good
faith efforts to resolve such dispute within a reasonable period of time. Should
the parties fail to reach agreement after thirty (30) days of good faith
negotiations, the parties agree to submit said dispute to binding arbitration.
Said arbitration shall take place in Los Angeles, California, in accordance with
the rules of the American Arbitration Association. The arbitration panel shall
consist of one arbitrator selected by the American Arbitration Association.

         10.2. The arbitration proceedings conducted pursuant hereto shall be
confidential. Neither party shall disclose or permit the disclosure of any
information about the evidence adduced or the documents produced by the other
party in the arbitration proceedings or about the existence, contents or results
of the arbitration award without the prior written consent of such other party
except in the course of judicial, regulatory or arbitration proceeding or as may
be required by a governmental authority. Before making any disclosure permitted
by the preceding sentence, the party intending to make such disclosure shall
give the other party reasonable written notice of the intended disclosure and
afford the other party reasonable opportunity to protect its interests.

         10.3. The arbitrators shall set forth in writing their findings of fact
and conclusions of law and shall render their award based thereon. Said award
shall be a final and binding judgment enforceable by a court of competent
jurisdiction.

         10.4. The party for whom the outcome of the arbitrators' decision is
less favorable (as determined by the arbitrators) shall be responsible for
reimbursing the other party for all fees and expenses of such party that are
directly related to the arbitration proceeding (including reasonable attorneys'
fees).

<PAGE>

         IN WITNESS WHEREOF, the parties have executed this Agreement as of the
day and year first above written.

                                 SPECIALIZED HEALTH PRODUCTS INTERNATIONAL, INC.

                                 By: /s/ Jeffrey M. Soinski
                                     -----------------------------------
                                 Name:    Jeffrey M. Soinski
                                 Title:   President and CEO

                                 EXELINT INTERNATIONAL, COMPANY

                                 By: E. Hamid
                                     -----------------------------------
                                 Name:    E. Hamid
                                 Title:   President

NOTE:    This Agreement is approved and signed between EXEL and SHPI directly
         and no middleman or broker are involved. Any commission or broker fee
         is prohibited.

<PAGE>

                                    EXHIBIT A

         Minimum Purchase Requirements*

         Year                                  LiftLoc(R) Units
         -------------------------- -------------------------------------
         1st Contract Year                           **
         2nd Contract Year                           **
         3rd Contract Year                           **
         4th Contract Year                           **
         5th Contract Year                           **

**

Minimum Shipment Quantity
The minimum order quantity for any order shall be 10,000 units with a 5 case
minimum order per SKU.

Pricing
LiftLoc(R) Safety Infusion:

            Volume              Y-Site              Non Y-Site
                            Each      Case       Each      Case
         ---------------- -------------------- -------------------
         0 - 100,000         **         **        **        **
         100,000+            **         **        **        **
         ---------------- -------------------- -------------------

Patient Comfort Pad (TM):

$** for each case of 400 units

-----------------
The "**" marks the location of information that has been omitted and filed
separately with the Securities and Exchange Commission pursuant to a request for
confidential treatment.

<PAGE>

EXHIBIT A (Continued)

                                                                     Quantity
   Order Number         Needle Gauge x Length        Y-Site            Case
--------------------------------------------------------------------------------
LiftLoc(R) Safety Infusion Set
--------------------------------------------------------------------------------
     01019-75              19G. x 3/4"                 No              160
     01120-75              20G. x 3/4"                Yes              160
     01020-75              20G. x 3/4"                 No              160
     01022-75              22G. x 3/4"                 No              160
     01019-10              19G. x 1"                   No              160
     01020-10              20G. x 1"                   No              160
     01120-10              20G. x 1"                  Yes              160
     01022-10              22G. x 1"                   No              160
     01020-15              20G. x 1 1/2"               No              160
     01119-75              19 G. x 3/4"               Yes              160
     01122-75              22 G. x 3/4"               Yes              160
     01119-10              19 G. x 1"                 Yes              160
     01122-10              22 G. x 1"                 Yes              160
     01119-15              19 G. x 1 1/2"             Yes              160
     01120-15              20 G. x 1 1/2"             Yes              160
     01122-15              22 G. x 1 1/2"             Yes              160
     01019-15              19 G. x 1 1/2"              No              160
     01022-15              22 G. x 1 1/2"              No              160

Patient Comfort Pad
--------------------------------------------------------------------------------
     01000-01                 One Size                (NA)             400
--------------------------------------------------------------------------------Exhibit 10.17

                                LICENSE AGREEMENT

         THIS LICENSE AGREEMENT, made effective as of August 8, 2003 ("EFFECTIVE
DATE"), by and between Specialized Health Products, Inc., a corporation of the
State of Utah, having a place of business at 585 West 500 South, Bountiful, Utah
84010 (hereinafter referred to as "SHPI" or "LICENSOR") and Becton, Dickinson
and Company, a corporation of the State of New Jersey, having a place of
business at 1 Becton Drive, Franklin Lakes, New Jersey 07417 (hereinafter
referred to as "BD" or "LICENSEE"), SHPI and BD being hereinafter sometimes
jointly referred to as the "PARTIES".

                                   WITNESSETH:

         WHEREAS, SHPI owns or controls PATENTS and TECHNOLOGY (defined
hereinafter) related to components used as needle safety devices for medical
needles; and

         WHEREAS, BD desires to obtain and SHPI is willing to grant, certain
rights to the PATENTS and the TECHNOLOGY;

         NOW, THEREFORE, in consideration of the promises and mutual covenants
made herein and other good and valuable consideration, receipt of which is
hereby acknowledged, it is agreed by and between the PARTIES as follows:

                                 I. DEFINITIONS

         1.1 AGREEMENT YEAR means each consecutive year measured from the first
day of January and ending on the last day of December of such year.

         1.2 ASP or AVERAGE SELLING PRICE means the average price per unit of
LICENSED PRODUCT sold by BD during an AGREEMENT YEAR in a particular country to
a third party. For LICENSED PRODUCTS that are sold in trays, the ASP shall be
the imputed unit value of the LICENSED PRODUCT included in that tray, which
value shall be the same as the ASP for the same LICENSED PRODUCT sold as a
single sterile unit. **. "Price" means the gross invoice amount of sales of
LICENSED PRODUCT, less any returns or credits, rebates, excise, sales, use or
value added taxes, cash and trade discounts allowed, import duties and
commissions to agents, but without deduction for uncollected amounts. It is
understood by the parties that ASP may fluctuate on an annual basis throughout
the duration of the Agreement.

-------------------
The "**" marks the location of information that has been omitted and filed
separately with the Securities and Exchange Commission pursuant to a request for
confidential treatment.

<PAGE>

         1.3 SPINAL/EPIDURAL FIELD shall mean the use of the LICENSED PRODUCT
with spinal and epidural needles, spinal introducer needle and peripheral block
needles. SPINAL/EPIDURAL FIELD shall not include intravascular catheters or
catheter introducers.

         1.4 RADIOLOGY/BIOPSY FIELD shall mean the use of LICENSED PRODUCT with
radiology and biopsy needles, as set forth in Exhibit 1.4. RADIOLOGY/BIOPSY
FIELD shall not include intravascular catheters or catheter introducers.

         1.5 INITIAL AVAILABILITY means the first day of the first QUARTER after
the earlier of:

                  i) the first commercial sale of a LICENSED PRODUCT, or

                  ii) the later of ** after 510(k) approval is first received
         for LICENSED PRODUCT or completion of design verification under Section
         3.1 (c). Approval of the 510(k) shall be deemed first received when the
         FDA approves LICENSED PRODUCT for use in connection with both a spinal
         needle and an epidural needle.

         1.6 INVENTION means the inventions disclosed and described in the U.S.
patent applications and international patent applications listed in Exhibit 1.6
attached hereto.

         1.7 LICENSED PRODUCT means a needle or introducer, the manufacture,
use, import, promotion, offer for sale or sale of which, but for the license
granted hereunder, would infringe one or more VALID CLAIMS of a patent within
the PATENTS in the country into which such product is sold.

         1.8 NET UNITS means the number of units of the LICENSED PRODUCT sold
and shipped by BD to a purchaser.

         1.9 PATENTS means those U.S. patent applications and international
patent applications listed in Exhibit 1.3 hereto and those U.S. Patent and
international Patents that may issue from or based on (i) those patent
applications listed in Exhibit 1.3 attached hereto, (ii) any patent application
that may be filed in any country that claims the benefit of the filing date of
any of the patents or applications listed in Exhibit 1.3 hereto, (iii) all
continuation, continuing prosecution and divisional applications based on any of
the aforementioned applications, and (iv) all reissues, reexaminations, renewals
and/or extensions thereof.

         1.10 PROTOTYPE shall mean the safety device developed by SHPI and
disclosed to BD hereunder.

         1.11 QUARTER means a calendar quarter ending on the last day of March,
June, September or December of each calendar year.

         1.12 ROYALTY means any amount payable by LICENSEE in accordance with
Article III any sales of LICENSED PRODUCT within the TERRITORY and any
extensions thereof.

         1.13 SUBLICENSEE means any entity selected by BD and approved by SHPI
to which BD sublicenses any of its rights hereunder.

---------------
The "**" marks the location of information that has been omitted and filed
separately with the Securities and Exchange Commission pursuant to a request for
confidential treatment.

<PAGE>

         1.14 TECHNOLOGY means CONFIDENTIAL INFORMATION as defined in Section XI
including, where appropriate, all information, technical data or other know-how
which relates to the design, development, manufacture, use or sale of the
LICENSED PRODUCT (including but not limited to medical uses and methods, product
forms, specifications and manufacturing data) which SHPI owns or controls, and
which SHPI discloses and furnishes to LICENSEE hereunder.

         1.15 TERRITORY means the world.

         1.16 VALID CLAIM shall mean (a) a claim of an issued PATENT that has
not lapsed or become abandoned and that has not been declared invalid or
unenforceable by an unappealed or unappealable decision or judgment of a court
of competent jurisdiction and/or (b) a pending claim of any pending patent
application included within the definition of PATENTS.

         1.17 AFFILIATE means any corporation, company, partnership, joint
venture and/or firm which controls, is controlled by or is under common control
with a PARTY. As used in this paragraph, "control" means (a) in the case of
corporate entities, direct or indirect ownership of at least fifty percent (50%)
of the stock or shares having the right to vote for the election of directors,
and (b) in the case of non-corporate entities, direct or indirect ownership of
at least fifty percent (50%) of the equity interest with the power to direct the
management policies of such non-corporate entities. Unless otherwise specified,
the term BD and LICENSEE as used in this Agreement includes Becton, Dickinson
and Company and its AFFILIATES.

         1.18 **.

                              II. GRANT OF LICENSE

         2.1 SHPI hereby grants to LICENSEE, subject to the terms and conditions
set forth herein, an exclusive, world-wide right and license under the PATENTS
in the SPINAL/EPIDURAL FIELD to make, have made, use, promote, offer for sale,
sell and import LICENSED PRODUCT in the TERRITORY.

         2.2 SHPI hereby grants to LICENSEE the right to sublicense the PATENTS
in the SPINAL/EPIDURAL FIELD to one or more SUBLICENSEES upon LICENSOR's prior
approval, which approval shall not be unreasonably withheld. SHPI agrees not to
sell, license or grant rights to PATENTS for the SPINAL/EPIDURAL FIELD to third
parties. Further, SHPI agrees to expressly exclude the field of spinal
introducer needles from any licenses to third parties. Notwithstanding, SHPI
disclaims any obligation to ensure that products sold, licensed or to which any
rights are granted to third parties are not used as spinal introducer needles.

---------------
The "**" marks the location of information that has been omitted and filed
separately with the Securities and Exchange Commission pursuant to a request for
confidential treatment.

<PAGE>

         2.3 SHPI hereby grants to LICENSEE, subject to the terms and conditions
set forth herein, a non-exclusive, world-wide right and license under the
PATENTS in the RADIOLOGY/BIOPSY FIELD to make, have made, use, promote, offer
for sale, sell and import LICENSED PRODUCT in the TERRITORY.

         2.4 Subject to the reversion set forth in Section 5.2, 5.3 and 5.5,
SHPI grants to BD a fully paid up, non-exclusive license to the TECHNOLOGY in
the SPINAL/EPIDURAL FIELD and RADIOLOGY/BIOPSY FIELD. Such grant of license to
the TECHNOLOGY shall not be deemed to be a grant of right to the PATENTS or any
other patents owned or controlled by SHPI. Rather, the grant of such license to
the TECHNOLOGY in the SPINAL/EPIDURAL FIELD and RADIOLOGY/BIOPSY FIELD shall be
subject to any rights to PATENTS, or other patents owned or controlled by SHPI.

                                 III. PAYMENTS

         3.1 In consideration of the license and rights granted by SHPI to
LICENSEE to the TECHNOLOGY hereunder, LICENSEE shall pay SHPI:

                  a) ** Dollars ($**) within thirty (30) days of the EFFECTIVE
         DATE;

                  b) ** Dollars ($**) upon approval of the first device 510(k)
         application, received from the Food and Drug Administration relating to
         LICENSED PRODUCT;

                  c) ** Dollars ($**) upon completion of design verification,
         including production-quality parts, stampings, molding, and assembly
         performance (that is, the end of design and development phase); and

                  d) ** Dollars ($**) upon INITIAL AVAILABLITY.

         3.2 LICENSEE shall pay SHPI an annual royalty payment as follows:

                  a) for each unit of LICENSED PRODUCT sold by BD and its
         Sublicensees in the United States ("U.S.") and Canada, an annual
         royalty payment in the amount of ** percent (**%) on average selling
         price (ASP);

                  b) for each unit of LICENSED PRODUCT sold by BD and its
         Sublicensees in any region outside the United States ("U.S.") and
         Canada, an annual royalty payment in the amount of ** percent (**%) on
         ASP; and

                  c) for each unit of LICENSED PRODUCT which is sold by BD and
         its Sublicensees in any region in which there is no VALID CLAIM, but
         which is made in a region in which there is a VALID CLAIM, an annual
         royalty payment in the amount of ** percent (**%) on ASP.

----------------
The "**" marks the location of information that has been omitted and filed
separately with the Securities and Exchange Commission pursuant to a request for
confidential treatment.

<PAGE>

         3.3 In the event a VALID CLAIM is not allowed within five (5) years of
the EFFECTIVE DATE, BD may elect to terminate this Agreement. Alternatively, BD,
at its sole discretion, may elect to continue under the Agreement. If BD elects
to continue under the Agreement, the annual royalty payment shall be reduced
until such time a VALID CLAIM is allowed as follows:

                  a) for each unit of LICENSED PRODUCT sold by BD and its
         Sublicensees in the United States ("U.S.") and Canada, an annual
         royalty payment in the amount of ** percent (**%) on average selling
         price (ASP); and

                  b) for each unit of LICENSED PRODUCT sold by BD and its
         Sublicensees in any country outside the United States ("U.S.") and
         Canada, an annual royalty payment in the amount of ** percent (**) on
         ASP; and

                  c) for each unit of LICENSED PRODUCT which is sold by BD and
         its Sublicensees in any region in which there is no VALID CLAIM, but
         which is made in region in which there is a VALID CLAIM, an annual
         royalty payment in the amount of ** percent (**%) on ASP.

         3.4 BD shall deliver to SHPI written reports of Net Sales of LICENSED
PRODUCT for the QUARTER in which the LICENSED PRODUCT was sold, on or before the
forty-fifth (45th) day following the last day of the QUARTER. Such reports shall
include a calculation of the royalties due and be accompanied by any payment due
pursuant to Section 3.2, Section 3.3 and/or Section 3.5.

         3.5A In any one year period prior to an anniversary of the INITIAL
AVAILABILITY in which the royalty that is required in Section 3.2 or 3.3 does
not meet or exceed the amount of the minimum royalty due under this Section, BD
shall, with the payment made for that year, pay an amount ("INCREMENTAL
PAYMENT") as additional royalty sufficient to bring the total royalties payable
for such year up to an amount equal to the minimum royalty required hereby. Any
payments pursuant to this Section shall be made within sixty (60) days of the
date the payment is due. Specifically, BD shall have the following minimum
annual royalty obligations:

                  a) For the first year after INITIAL AVAILABILITY, the minimum
         annual royalty shall be the royalty that would have been due if BD had
         sold ** units of LICENSED PRODUCT in the United States during that
         period. If BD sells ** units or more of LICENSED PRODUCT during that
         period, the ASP used to calculate the minimum annual royalty shall be
         the ASP for the units of LICENSED PRODUCT actually sold by BD during
         this period. If BD sells less than ** units of LICENSED PRODUCT during

------------------
The "**" marks the location of information that has been omitted and filed
separately with the Securities and Exchange Commission pursuant to a request for
confidential treatment.

<PAGE>

         that period, the ASP shall be $** US per unit of LICENSED PRODUCT. For
         purposes of clarity, in the instance that BD sells no units of LICENSED
         PRODUCT during this period, the minimum annual royalty shall be $**;

                  b) For the second year after INITIAL AVAILABILITY, the minimum
         annual royalty shall be the royalty that would have been due if BD had
         sold ** units of LICENSED PRODUCT in the United States during that
         period. If BD sells ** units or more of LICENSED PRODUCT during that
         period, the ASP used to calculate the minimum annual royalty shall be
         the ASP for the units of LICENSED PRODUCT actually sold by BD during
         this period. If BD sells less than ** units of LICENSED PRODUCT during
         that period, the ASP shall be $** US per unit. For purposes of clarity,
         in the instance that BD sells no units of LICENSED PRODUCT during this
         period, the minimum annual royalty shall be $**; and

                  c) For the third year after INITIAL AVAILABILITY and each year
         thereafter, the minimum annual royalty shall be the royalty that would
         have been due if BD had sold ** units of LICENSED PRODUCT in the United
         States during that period. If BD sells ** units or more of LICENSED
         PRODUCT during that period, the ASP used to calculate the minimum
         annual royalty shall be the ASP for the units of LICENSED PRODUCT
         actually sold by BD during this period. If BD sells less than ** units
         of LICENSED PRODUCT during that period, the ASP shall be $** US per
         unit of LICENSED PRODUCT. For purposes of clarity, in the instance that
         BD sells no units of LICENSED PRODUCT during this period, the minimum
         annual royalty shall be $**.

         3.5B.  **

         3.6 BD shall keep accurate books and records of sales of LICENSED
PRODUCT and of all payments due SHPI hereunder for one year after the Term of
the Agreement. BD shall contractually obligate all BD sublicensees to keep
accurate books and records of Net Sales of LICENSED PRODUCT and of all data
necessary for the computation of royalties hereunder for the relevant sale
period.

         3.7 SHPI shall have the right to nominate an independent accountant
acceptable to and approved by BD who shall have access to BD and/or its
Sublicensees records during reasonable business hours, upon executing an
appropriate confidentiality agreement, for the purpose of verifying the royalty
payable as provided for in this Agreement for the two (2) preceding years, but
this right may not be exercised more than once in any year, and the accountant
shall disclose to SHPI only information relating solely to the accuracy of the
royalty report and the royalty payments made in accordance with this Agreement.
BD shall impose similar contractual obligations on its sublicensees to allow an
independent public accountant to inspect the sublicensee's books and records to
verify payments under such sublicense.

------------------
The "**" marks the location of information that has been omitted and filed
separately with the Securities and Exchange Commission pursuant to a request for
confidential treatment.

<PAGE>

         3.8 Royalties and other payments under this Agreement shall be made in
United States dollars. To the extent sales requiring a royalty may be made by BD
in a country other than the United States, such royalties shall be made by BD in
United States dollars on the basis of conversion, from the currency of such
other country, at the rate of exchange recited in the report entitled "Rates of
Exchange" issued monthly by BD's International Finance Department which provides
spot exchange rates for each other country where sales were made, on the last
business day of the calendar quarter when the sales occurred, and shall be paid
at the time and in the manner set forth herein, provided however, that
royalties/payments based on any sales under this Agreement shall be payable to
SHPI only after deducting for exchange and all other charges due governments,
including withholding taxes, arising from the origin and transmittal of such
royalties, and further provided that the foregoing is subject to the right to
make payment in any country where currency is blocked and where legal conversion
of the currency billed cannot be made into United States Dollars by depositing
such payments in SHPI's name in a bank designated by SHPI within such country.
BD shall pay all withheld amounts to the appropriate tax or governmental
authorities as required by law and furnish SHPI with official tax receipts or
other appropriate evidence issued by the appropriate authorities to assist SHPI
in supporting a claim for income tax credit in respect of any sums so withheld.

         3.9 The payment by BD of the monies due under this Section 3 is
considered complete satisfaction of any duty imposed upon BD to commercially
exploit LICENSED PRODUCTS and is accepted by SHPI in lieu of best or reasonable
efforts obligation on the part of BD. Nothing in this Agreement shall impose
upon BD an obligation to use its best or reasonable efforts to create, continue
or maximize sales of LICENSED PRODUCTS or prevent BD from making, using,
offering to sell, selling, or importing or causing to be made, used, offered for
sale, sold or imported from, to or in any place in the world, products
competitive in nature to LICENSED PRODUCTS. Nothing herein shall in any way
limit BD's free and exclusive right to determine in its sole discretion the
timing or manner of marketing, manufacturing or advertising LICENSED PRODUCTS,
so long as such marketing, manufacturing or advertising is in compliance with
local laws and regulations. Notwithstanding the foregoing, the parties recognize
SHPI's right to terminate this License Agreement as set forth in Section 5.5

         3.10 ** For the sake of clarity, it is agreed that transfer of a
LICENSED PRODUCT from or to Becton Dickinson & Company to or from a BD AFFILIATE
shall not be deemed as sale of LICENSED PRODUCT and shall not be deemed a
royalty-generating event.

------------------
The "**" marks the location of information that has been omitted and filed
separately with the Securities and Exchange Commission pursuant to a request for
confidential treatment.

<PAGE>

                          IV. RESEARCH AND DEVELOPMENT

         4.1 BD shall reimburse SHPI for all pre-approved "out-of-pocket"
expenses accrued after the EFFECTIVE DATE, including travel and related expenses
for manufacturing and development activities at BD's request or approved by BD,
for SHPI's performance of its responsibilities under this Agreement (**). Weekly
team meetings will be the mechanism for approving out-of-pocket expenses.

         4.2 SHPI and BD shall cooperate to prepare and file an application for
510(k) device approval for the LICENSED PRODUCT that is acceptable to both
PARTIES. BD shall elect which LICENSED PRODUCT shall by submitted for 510(k)
approval. SHPI shall be responsible for design verification, design validation,
the Design Control and Design History File, and the successful 510(k) regulatory
submission(s) relative to the elected spinal and epidural LICENSED PRODUCT. SHPI
shall provide BD with complete and accurate copies of any communication to and
from the Food and Drug Administration with respect to any LICENSED PRODUCT, and
all relevant design data and information. BD, at its expense, shall assist and
cooperate with SHPI through the design verification, design validation, and
regulatory submission and activities. BD shall participate in weekly design
meetings, conference calls, and formal design review meetings.

         4.3 BD shall be free to file additional requests for 510(k) approval
for LICENSED PRODUCTS, using any materials, data and information developed in
connection with the request described in Section 4.2. Any efforts by SHPI in
preparing such a request shall be at BD's expense, at rates to be mutually
agreed upon by BD and SHPI.

         4.4 SHPI shall be responsible for the development of machined prototype
components and stamped components. SHPI shall also be responsible for
coordination of production stamping tool and of prototype mold parts.

         4.5 SHPI shall be responsible for coordination of the development of
proof-in-principle needle assembly machine and development of a prototype
process for assembly of molded parts over the metal component.

         4.6 BD shall be responsible for manufacturing, final product assembly,
promotional materials, packaging, distribution and sale of LICENSED PRODUCT.
SHPI shall assist BD on a reasonable basis concerning the final assembly machine
for LICENSED PRODUCT.

         4.7 SHPI shall own inventions, whether patentable or not, first
conceived solely by employees of SHPI. BD shall own inventions, whether
patentable or not, first conceived solely by employees of BD. SHPI and BD shall
jointly own title to any and all intellectual property first conceived jointly
or discovered jointly by SHPI's employees or personnel and BD's employees or

------------------
The "**" marks the location of information that has been omitted and filed
separately with the Securities and Exchange Commission pursuant to a request for
confidential treatment.

<PAGE>

personnel, including but not limited to inventions, processes, manufacturing
techniques, know how, and information, whether patentable or not, arising in
connection with the performance of services under this Agreement. Subject to any
intellectual property rights pre-existing to or independent of such jointly
conceived inventions, each party grants to the other a royalty-free,
non-exclusive worldwide license, with the right to sublicense, on all rights to
jointly conceived inventions.

                           V. EFFECTIVE DATE AND TERM

         5.1 This Agreement shall commence on the EFFECTIVE DATE and shall
continue thereafter until the expiration of the longest-lived patent of the
PATENTS, unless sooner terminated in accordance with the provisions of Sections
3.3, 5.2, 5.3, 5.4 or 5.5.

         5.2 BD shall have the right to terminate this Agreement upon ** written
notice to SHPI. Any termination under this Section may not take effect before
the ** anniversary of INITIAL AVAILABILITY. Upon termination under this Section,
BD shall be responsible for any minimum royalties due under Section 3.5 for the
period before termination but after the immediately previous anniversary of the
INITIAL AVAILABILTIY on a pro rata basis. Upon termination under this Section
5.2, all rights to the PATENTS, the TECHNOLOGY and to the 510(k)'s prepared and
submitted by SHPI for devices including the TECHNOLOGY revert to SHPI. Such
reversion of rights to 510(k)'s for devices including the TECHNOLOGY shall not
transfer, or deem to transfer, to SHPI and shall not be deemed to transfer any
rights to any other intellectual property owned by BD related to the subject
device.

         5.3 Except as otherwise provided in this Agreement, in the event of a
material breach or default by either of the PARTIES hereto of any term or
provision of this Agreement on their respective parts to be observed or
performed, the PARTY not in breach or default shall have the right to give the
other PARTY notice thereof, whereupon the PARTY receiving such notice shall have
forty-five (45) days to cure or cause the cure of such breach or default, or if
the same cannot reasonably be cured within such forty-five (45) days, the PARTY
receiving such notice shall, within said period, commence or cause the
commencement of such cure and thereafter continue to diligently prosecute or
cause the prosecution of cure of the same. If such breach or default is cured,
this Agreement shall remain in full force and effect. If such breach or default
is not cured, this Agreement may be terminated, subject to Articles XII and
XIII, by the non-defaulting PARTY. The right of either PARTY to terminate this
Agreement shall not be affected in any way by its waiver, or failure to take
action with respect to any previous default. Upon termination under this Section

------------------
The "**" marks the location of information that has been omitted and filed
separately with the Securities and Exchange Commission pursuant to a request for
confidential treatment.

<PAGE>

         5.3, all rights to the TECHNOLOGY and to the 510(k)'s prepared and
submitted by SHPI for devices including the TECHNOLOGY revert to SHPI. Such
reversion of rights to 510(k)'s for devices including the TECHNOLOGY shall not
transfer, or deem to transfer, to SHPI and shall not be deemed to transfer any
rights to any other intellectual property owned by BD related to the subject
device.

         5.4 In the event that LICENSEE is dissolved, whether voluntarily or
compulsorily (except in the case of a dissolution for the purposes of
recapitalization and/or non-bankruptcy reorganizations where the resulting
entity agrees to be bound by the terms of this Agreement), or has appointed a
receiver or trustee of its assets or a substantial part thereof, or enters into
a composition with creditors, this Agreement shall thereupon terminate and all
rights granted to Licensee hereunder shall immediately revert to and vest in
SHPI; provided, however, in the case of an involuntary appointment of receivers
or trustees, such appointment shall not result in termination of the license if
the LICENSEE endeavors to set aside the appointment of the receiver or trustee
and is successful in setting aside the receiver or trustee within ninety (90)
days of appointment.

         5.5 In the event that BD has not commercially exploited the LICENSED
PRODUCT or the rights granted hereunder within three (3) years of INITIAL
AVAILABILITY, LICENSOR shall have the right to terminate this Agreement upon
sixty (60) days written notice to BD. If this right is not exercised by
LICENSOR, the right shall expire upon the commercial exploitation of LICENSED
PRODUCT by BD or the rights granted hereunder by SUBLICENSEES of BD. Upon
termination under this Section 5.5, all rights to the TECHNOLOGY and to the
510(k)'s prepared and submitted by SHPI for devices including the TECHNOLOGY
revert to SHPI. Such reversion of rights to 510(k)'s for devices including the
TECHNOLOGY shall not transfer, or deem to transfer, to SHPI and shall not be
deemed to transfer any rights to any other intellectual property owned by BD
related to the subject device.

                                VI. INFRINGEMENT

         6.1 In the event that either PARTY becomes aware of an infringement of
the PATENTS by a third party, it promptly shall notify the other PARTY in
writing to that effect. If the infringement is in the SPINAL/EPIDURAL FIELD, BD
shall be permitted, but not required, to bring suit and to control the conduct
thereof against the alleged infringer of any claims of any PATENTS, **. At BD's
request, SHPI will reasonably cooperate with BD in any suit for infringement of
the PATENT brought by BD, including being joined as a party plaintiff to such
suit, against a third party. **. In the event BD exercises the privileges herein
conferred, **. Notwithstanding the foregoing, **.

----------------
The "**" marks the location of information that has been omitted and filed
separately with the Securities and Exchange Commission pursuant to a request for
confidential treatment.

<PAGE>

         6.2 If, after the expiration of ninety (90) days from the date of such
notice, BD has not brought suit against the third party infringer, then SHPI
shall have the right after such ninety (90) day notice period, but not the
obligation, to bring suit against such infringer and, if a court of competent
jurisdiction determines it is necessary, to join BD as a party, **. At SHPI's
request, BD will reasonably cooperate with SHPI in any suit for infringement of
the PATENT brought by SHPI, including being joined as a party plaintiff to such
suit, against a third party. **. Notwithstanding the foregoing, **.

         6.3 In the event that any third party brings proceedings challenging
the validity of the PATENTS other than in the context of an infringement suit,
the PARTIES shall notify each other in writing to that effect. During the ninety
(90) day period after such notice, SHPI will have the right, but not the
obligation, to contest such proceedings. SHPI shall bear the expenses of any
such proceeding. SHPI shall have the final decision on all matters relating to
such proceeding and any settlement discussions. At SHPI's request, BD will
reasonably cooperate with SHPI in any suit for infringement of the PATENT
brought by SHPI, including being joined as a party plaintiff to such suit,
against a third party. **.

         6.4 If, after the expiration of the ninety (90) days from the date of
such notice, SHPI has not engaged in the proceeding, then LICENSEE shall have
the right after such ninety (90) day notice period, but not the obligation, to
contest such proceedings and join SHPI as a party provided that LICENSEE shall
bear all expenses of such proceeding. SHPI will reasonably attempt to cooperate
with LICENSEE in any such proceedings challenging the validity of the PATENTS
and shall have the right to consult with LICENSEE and to participate in and be
represented by independent counsel in such litigation at its own expense. **.
Where it is necessary for LICENSEE to have standing to contest the proceedings,
SHPI shall assign limited concurrent rights to the licensed PATENTS for the
terms of the proceedings. Notwithstanding the foregoing, **.

         6.5 Nothing contained in this ARTICLE VI shall be construed to in any
way limit or interfere with SHPI's right to bring suit and control the conduct
thereof for any and all claims relating to LICENSED PATENTS outside of the
SPINAL/EPIDURAL FIELD.

                       VII. PATENT PROSECUTION AND MARKING

         7.1 SHPI shall use reasonable commercial efforts to file and prosecute
patent applications, and shall maintain all patents, licensed under LICENSED
PATENTS.

-----------------
The "**" marks the location of information that has been omitted and filed
separately with the Securities and Exchange Commission pursuant to a request for
confidential treatment.

<PAGE>

         7.2 SHPI shall advise BD promptly of any patents issuing that are
LICENSED PATENTS. BD shall use reasonable commercial efforts to mark all
LICENSED PRODUCTS with the appropriate patent marking in compliance with all US
and foreign jurisdiction laws in respect of patent marking, if any, but the
selection, location and particulars of such marking shall be at BD's discretion.

                             VIII. PRODUCT LIABILITY

         LICENSEE shall be responsible for its acts and omissions with respect
to the manufacture, packaging and sale of the LICENSED PRODUCT. **.

                                IX. FORCE MAJEURE

         The obligations of either PARTY to perform under this Agreement shall
be excused if such failure to perform or any delay is caused, in whole or in
part, by reason beyond the reasonable control of such PARTY, including without
limitation, acts of God, embargo, law or governmental regulation, compliance
with any government request or directive, war, terrorist acts, riot,
insurrection, destruction of production facilities or materials by fire,
earthquake or storm, labor disturbance, epidemic, failure of public utilities or
common carriers or any other cause whether similar or dissimilar to those
enumerated which is reasonably beyond the control of the PARTY obligated to
perform ("Force Majeure"). Such delay shall be excused during the continuance of
and to the extent of such Force Majeure, without liability for any failure to
perform this AGREEMENT. The PARTY claiming Force Majeure shall promptly notify
the other PARTY of the termination of such event. Upon the occurrence of such an
event, the duties and obligations of the PARTIES shall be suspended for the
duration of the event preventing proper performance under this Agreement. The
affected PARTY shall resume the performance of its obligations as soon as
practicable after the Force Majeure event ceases. In the event that LICENSEE is
unable to manufacture or have manufactured any LICENSED PRODUCT for a period of
more than ninety (90) days as a result of an event of Force Majeure and as a
consequence does not, during any AGREEMENT YEAR, manufacture or have
manufactured sufficient units of the LICENSED PRODUCT to meet the minimum NET
UNITS for such AGREEMENT YEAR, as set forth in section 3.5, its obligation under
Section 3.5 to pay ROYALTIES on such minimum NET UNITS will be excused for the
AGREEMENT YEAR during which the Force Majeure event prevented its fulfillment of
such obligation, and that obligation and all succeeding obligations of the same
sort, if any, shall be deferred to the next succeeding AGREEMENT YEAR of each.

-----------------
The "**" marks the location of information that has been omitted and filed
separately with the Securities and Exchange Commission pursuant to a request for
confidential treatment.

<PAGE>

                  X. INDEMNIFICATION, INSURANCE AND DISCLAIMER,
                         REPRESENTATIONS AND WARRANTEES

         10.1 LICENSEE agrees that it shall be solely responsible for all the
expenses connected with its business related to the manufacture and sale of
LICENSED PRODUCT, and for taxes and levies of any and all kinds in connection
with that business and the income therefrom and SHPI shall not be liable for any
such expenses, taxes or levies, or disbursements otherwise paid and incurred,
except as provided in Section 3.8.

         10.2 SHPI hereby represents and warrants to LICENSEE as follows:

                  (a)Neither the execution nor delivery of this Agreement nor
         the consummation of the transactions provided for herein, violates any
         agreement, lien, instrument, decree, order or judgment to which the
         PATENTS, the TECHNOLOGY or SHPI or any of its officers, directors,
         shareholders or partners is a party or by which it or they are bound.
         SHPI has the authority to grant to LICENSEE the licenses of the
         PATENTS, the TECHNOLOGY and the INVENTION that are licensed and
         transferred pursuant to this Agreement. Should SHPI acquire, after the
         EFFECTIVE DATE, any patent infringed by a LICENSED PRODUCT, such
         patents shall be deemed PATENTS to the extent necessary or useful to
         make, have made, use, sell, offer to sell or import LICENSED PRODUCTS.

                  (b) There are no licenses or other similar agreements entered
         into by SHPI pertaining to or affecting any of the PATENTS, the
         INVENTION or the TECHNOLOGY, relating to safety device components for
         the needle safety feature for medical needles in the SPINAL/EPIDURAL
         FIELD and RADIOLOGY/BIOPSY FIELD, which would otherwise diminish the
         licenses granted to LICENSEE under this Agreement.

                  (c) There are no patents owned or controlled by SHPI, other
         than the PATENTS licensed to BD according to the terms of this
         Agreement, having claims that would cover BD's making, having made,
         using, selling, offering for sale or importing LICENSED PRODUCT.

                  (d) There are no suits pending that challenge the validity of
         any of the patents within PATENTS. (e) There are no third party
         obligations, which would adversely affect SHPI's performance under this
         Agreement.

         10.3 The Parties hereby agree to indemnify and hold each other harmless
from and against all liabilities, claims, losses, damages, costs and expenses
(including attorneys' fees) resulting from or arising in connection with the
breach by SHPI or BD of any of the warranties set forth in this Article X.
Notwithstanding the foregoing, neither party shall be liable hereunder for
special, indirect, consequential or incidental damages, including, but not
limited to, loss of actual or anticipated profits or revenues, loss by reason of
shutdown, loss of use, loss of accruing interest, nonoperation or increased
expense of manufacturing or operation, delay, or any damages arising in
connection with the reconstruction of or loss of other property or equipment or
any loss of reputation or public image.

         Upon receiving notice of any claim for liability under this Article,
the indemnified party shall promptly notify the indemnifying party in writing;
provided, however, that failure to give notice shall not limit or otherwise
reduce the indemnity provided for in this Agreement. The indemnifying party may,
in its sole discretion, assume and conduct the legal defense of the indemnified
party in any suit that could result in claims under this Article. Unless made
with the express written consent of the indemnifying party, no sums paid by the
indemnified party in settlement of any claim shall be recoverable under this
Article.

         10.4 With respect to SHPI, nothing in this Agreement shall be construed
as:

                  (a) A warranty or representation that any patent applications
         filed or that may be filed disclosing and claiming any aspect of the
         PATENTS will mature into issued patents; or

                  (b) Granting by implication, estoppel, or otherwise any
         licenses or rights other than those expressly granted in this
         Agreement.

         10.5 Each of the PARTIES represents and warrants that it has not
accepted and will not accept any commitments or restrictions which will
materially affect the value of the rights granted in this Agreement to the other
PARTY.

         10.6 If BD is sued by a third party charging infringement of a patent
resulting from the manufacture, sale, offer to sell or use of a LICENSED
PRODUCT, BD shall promptly notify SHPI. BD shall have the right to defend
against such charge of infringement, and during the period in which such
litigation is pending, **.

         10.7 **

         10.8 LICENSOR MAKES NO WARRANTIES, EXPRESS, IMPLIED OR STATUTORY, WITH
RESPECT TO THE LICENSED INTELLECTUAL PROPERTY NOT EXPRESSLY SET FORTH IN THIS
AGREEMENT. THE LICENSED INTELLECTUAL PROPERTY IS MADE AVAILABLE TO LICENSEE
STRICTLY ON AN "AS IS" BASIS. LICENSOR DOES NOT WARRANT THAT THE LICENSED
INTELLECTUAL PROPERTY IS ERROR FREE OR THAT IT WILL MEET LICENSEE'S
REQUIREMENTS. ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A
PARTICULAR PURPOSE ARE EXPRESSLY DISCLAIMED AND EXCLUDED.

-----------------
The "**" marks the location of information that has been omitted and filed
separately with the Securities and Exchange Commission pursuant to a request for
confidential treatment.

<PAGE>

         10.9 LICENSEE will in all material respects comply with all applicable
local, foreign and international law during the term of this Agreement. LICENSEE
further agrees to register this Agreement as, where, and when required by law,
rule, or regulation of any government or governmental entity, and to pay when
due all costs and fees connected therewith, and to otherwise fully comply with
all applicable laws, rules, and regulations of any government or governmental
authority.

         10.10 If BD is sued by a third party as a result of SHPI's selling or
licensing any product under the rights reserved to itself, SHPI shall hold BD
free, clear, and harmless from any and all costs and expenses of such
litigation, including attorneys' fees.

         10.11 LICENSEE hereby covenants that it will not, directly or
indirectly, export, license, distribute, sell, transfer or dispose of any
products sold as a result of this Agreement to or within any country in
contravention of any applicable laws, including but not limited to export
control laws. LICENSEE shall require that its distributors covenant to comply
with the prohibitions and restrictions set forth in the prior sentence. If
LICENSEE shall become aware that one of its distributors has exported or
distributed LICENSED PRODUCT in contravention of any applicable law, LICENSEE
shall immediately notify SHPI thereof. LICENSEE shall then immediately (i) cease
making LICENSED PRODUCT available to such distributor, and (ii) use its best
efforts to prevent any further contravention of law by such distributor.

                          XI. CONFIDENTIAL INFORMATION

         11.1 The term "Confidential Information" shall mean the terms and
conditions of this Agreement and all financial, technical and other information,
including all copies thereof (including, without limitation, all agreements,
discoveries, ideas, designs, specifications, drawings, techniques, models, data,
programs, documentation, processes, know-how, customer lists, marketing plans,
books, logs, charts, records, studies, reports, etc.) which may be furnished or
disclosed to recipient by, or acquired by recipient directly or indirectly from,
the disclosing PARTY or its Affiliates, including as a result of an inspection
of any facility of the disclosing PARTY or its Affiliates, or disclosing PARTY's
licensors, licensees or customers. To be considered Confidential Information,
any written information must be marked "confidential" and any information
disclosed in any form other than a writing must be reduced to writing with
thirty (30) days of the initial disclosure of such information, marked
"confidential," and provided to the recipient. For purposes of this Agreement,
Confidential Information shall not include, and the obligations herein shall not
apply to, information that: (a) was legally in the public domain prior to the
time of disclosure to the recipient, (b) is now or subsequently becomes
generally available to the public through no fault of recipient; (c) recipient
can demonstrate was rightfully in its possession prior to disclosure to
recipient by the disclosing PARTY; (d) is independently developed by recipient
without the use of any Confidential Information provided by the disclosing
PARTY; (e) recipient rightfully obtains from a third party who has the right,
without obligation to the disclosing PARTY, to transfer or disclose such
information; or (f) is required by law, regulation, rule, act, or order of any
governmental authority or agency to be disclosed by the receiving PARTY
provided, that in all cases the PARTY receiving the Confidential Information
shall, to the extent permitted, give the other PARTY prompt notice of the
pending disclosure and shall cooperate in such other PARTY's attempts, at such
other PARTY's sole expense, to seek an order maintaining the confidentiality of
the Confidential Information.

<PAGE>

         11.2 Each PARTY agrees not to use any Confidential Information
disclosed by the other PARTY for any purpose except as outlined in this
Agreement. Each PARTY agrees not to disclose any Confidential Information
received from the other PARTY to third parties or to employees of the recipient,
except to those employees who are required to have the Confidential Information
in connection with the performance of such PARTY hereunder.

         11.3 Each PARTY agrees to take all reasonable measures to protect the
secrecy of and prevent the disclosure and unauthorized use of the other PARTY's
Confidential Information. Without limiting the foregoing, the recipient shall
take at least those measures that the recipient takes to protect its own
Confidential Information of a like nature. A recipient shall immediately notify
the disclosing PARTY in the event that it becomes aware of any unauthorized use
or disclosure of the disclosing PARTY's Confidential Information.

         11.4 All Confidential Information is provided "as is". Neither PARTY
makes any warranties, express, implied or otherwise, regarding its accuracy,
completeness or performance.

         11.5 All documents and other tangible objects containing or
representing Confidential Information of a disclosing PARTY and all copies
thereof which are in the possession of a recipient shall be and remain the
property of the disclosing PARTY and shall be promptly returned to the
disclosing PARTY upon the disclosing PARTY's request, unless the retention of
such Confidential Information is required in connection with any performance or
usage under this Agreement and subject to retention of one (1) complete record
copy thereof to monitor compliance with this Agreement.

         11.6 Each PARTY hereby acknowledges that each PARTY's Confidential
Information is and shall continue to be the exclusive property of such PARTY,
whether or not disclosed or entrusted to the other PARTY pursuant to this
Agreement.

         11.7 The confidentiality requirements under this Article XI shall
survive until such time as all Confidential Information disclosed hereunder
becomes publicly known and made generally available through no action or
inaction of recipient, not to exceed a maximum of three (3) years from the
termination of this Agreement.

         11.8 Effective from the date of commencement of discussions concerning
this License Agreement, any person who makes or provides an oral or written
statement to any Party (or any person for whose benefit a statement is made or
provided to a Party), as to the potential tax consequences that may result from
this License Agreement, shall provide express written authorization to that
Party in substantially the following form:

         [Name of Party] (and each employee, representative, or other agent of
         [name of Party]) may disclose to any and all persons, without
         limitation of any kind, the tax treatment and tax structure of this
         License Agreement and all materials of any kind, including opinions or
         other tax analyses that are provided to [name of Party] relating to
         such tax treatment and tax structure. However, the foregoing does not
         constitute an authorization to disclose the identity of any existing or
         future Party to this License Agreement or their affiliates, agents or
         advisers, or, except to the extent relating to such tax structure or
         tax treatment, any specific pricing terms or commercial or financial
         information.

<PAGE>

Such written authorization shall be provided no later than 30 days from the day
the person providing such written authorization first makes or provides a
statement to a Party regarding the tax consequences of the transaction.

                  XII. RIGHTS AND OBLIGATIONS UPON TERMINATION

         Any termination of this Agreement shall be without prejudice to the
rights of either PARTY against the other which may have accrued up to the date
of such termination and shall be without prejudice to the right of LICENSEE (i)
to dispose of any inventory of the LICENSED PRODUCT manufactured up to the date
of such termination, and (ii) for a period of up to six (6) months following
termination, to complete binding contracts then in existence subject to the
payments thereon as agreed to herein.

                                XIII. ASSIGNMENT

         This Agreement shall not be assignable by either PARTY without the
prior written consent of the other PARTY, except to the successor or assignee of
all or substantially all of its business. It is expressly understood and agreed,
however, that the assignor of any rights hereunder shall remain bound by the
obligations thereof.

                               XIV. MISCELLANEOUS

         14.1 Nothing contained herein shall constitute the PARTIES as partners
or joint venturers and neither PARTY shall be the agent of or have the power to
incur any obligations on behalf of or to pledge the credit of the other PARTY in
any manner whatsoever.

         14.2 The failure or delay by either PARTY hereto in the enforcement of
any rights under this Agreement shall not be deemed a waiver or modification
thereof and either PARTY may within the time provided by applicable law commence
appropriate legal proceedings to enforce any or all of such rights.

         14.3 Notices given pursuant to this Agreement shall be sent to the
addresses set forth in the opening paragraph of this Agreement, or at such other
address as a PARTY may specify in accordance herewith, and shall be deemed to
have been received according to the following provisions:

                  (a) In the case of the personal delivery of the notice, the
         notice shall be deemed to have been received on the actual day of
         delivery or on the next following working day if delivered after 5:00
         p.m. on any working day.

                  (b) If notice is sent by certified mail to the address of the
         PARTY referred to herein or such other address as may be provided in
         writing by a PARTY from times to time, such notice to be deemed to have
         been received not later than on the fifth (5th) day after posting or
         earlier, if receipt is confirmed in writing.

                  (c) If notice is sent by cable, telegram, e-mail, overnight
         courier, or facsimile transmission, the notice shall be deemed to have
         been received on the working day next following the day of sending
         (provided proof can be shown that the notice was received by the
         intended recipient).

<PAGE>

         Notices sent to SHPI shall be addressed to:

                  President
                  Specialized Health Products, Inc.
                  585 West 500 South
                  Bountiful, Utah 84010
                  Fax: (801) 298-1759

         Notices sent to LICENSEE shall be sent to:

                  Vice President
                  Infusion Therapy Systems and Technique Products
                  Becton, Dickinson and Company
                  9450 South State Street Sandy, Utah 84070
                  Fax: (801) 565-2555

         with a copy to:

                  Chief Intellectual Property Counsel
                  Becton Dickinson and Company
                  1 Becton Drive
                  Franklin Lakes, New Jersey 07417
                  Fax: (201) 848-9228

         14.4 This Agreement sets forth the entire agreement and understanding
between the PARTIES relating to the subject matter of this Agreement and merges
all prior negotiations between the PARTIES. Neither of the PARTIES shall be
bound by any conditions, undertakings, warranties or representations with
respect to the subject matter of this Agreement other than as expressly provided
in this Agreement, or if subsequent to the date hereof, as may be made in
writing and signed by the PARTIES to be bound thereby.

         14.5 No pubic announcement or other disclosure to any third party
concerning the terms or existence of this Agreement or of the relationship
created thereby shall be made, either directly or indirectly, by either PARTY
except as may be legally required, without first obtaining the approval of the
other PARTY and agreement upon the nature and text of such announcement or
disclosure, which approval shall not be unreasonably withheld. The PARTY
desiring to make such public announcement or other disclosure shall inform the
other PARTY of the proposed announcement or disclosure in reasonably sufficient
time prior to public release and shall provide the other PARTY with a written
copy thereof, in order to allow such other PARTY to comment upon and revise such
announcement or disclosure. If legally required to disclose any information
regarding this Agreement, the PARTY so required will consult with the other
PARTY regarding such disclosure and shall make such reasonable changes as may be
requested by such other PARTY in the text of such disclosure, to the extent
compatible with the legal requirements of such disclosure.

         14.6 If any term or provision of this Agreement shall for any reason be
held invalid, illegal or unenforceable in any respect, such invalidity,
illegality or unenforceability shall not affect any other term or provision
hereof, and this Agreement shall be interpreted and construed as if such term or
provision, to the extent the same shall have been held to be invalid, illegal or
unenforceable, had never been contained herein.

         14.7 No waiver or modification of any of the terms of this Agreement
shall be valid unless in writing and signed by an authorized representative of
the Parties. Failure by either Party to enforce any rights under this Agreement
shall not be construed as a waiver of such rights, nor shall a waiver by either
Party in one or more instances be construed as constituting a continuing waiver
or as a waiver in other instances.

<PAGE>

         14.8 Should a dispute arise under this Agreement, the PARTIES shall
consider resolution of the dispute and, their sole discretions, may elect to
resolve such dispute in accordance with the dispute resolution process set forth
in Exhibit 14.8 hereof. The dispute resolution process of Exhibit 14.8 shall
only proceed upon the mutual consent of the PARTIES. This shall not be construed
as requiring that the PARTIES agree to resolve any such dispute in accordance
with Exhibit 14.8.

         14.9 The headings used in this Agreement are for convenience and
reference purposes only and shall not affect the meaning or interpretation of
this Agreement.

         14.10 This Agreement shall be construed in accordance with the laws of
the State of Utah, without regard to its conflict of laws provisions.

         IN WITNESS WHEREOF, the PARTIES hereto have caused this Agreement to be
executed as of the date first above written.

BECTON, DICKINSON AND COMPANY                  SPECIALIZED HEALTH PRODUCTS, INC.

By:  /s/ Grank Guido                           By:  /s/ Jeffrey M. Soinski
-----------------------------                  ---------------------------------
Frank Guido                                    Jeffrey M. Soinski, President
President, Medical Surgical

<PAGE>

EXHIBIT 1.4

                                  BD Code    Description
                        1            **      **
                        2            **      **
                        3            **      **
                        4            **      **
                        5            **      **
                        6            **      **
                        7            **      **
                        8            **      **
                        9            **      **
                        10           **      **
                        11           **      **
                        12           **      **
                        13           **      **
                        14           **      **
                        15           **      **
                        16           **      **
                        17           **      **
                        18           **      **
                        19           **      **
                        20           **      **
                        21           **      **
                        22           **      **
                        23           **      **
                        24           **      **
                        25           **      **
                        26           **      **
                        27           **      **
--------------------
The "**" marks the location of information that has been omitted and filed
separately with the Securities and Exchange Commission pursuant to a request for
confidential treatment.

<PAGE>

EXHIBIT 1.6

                COUNTRY        SERIAL NO.        FILING DATE      SHPI DOCKET
         ------------------ ----------------- ---------------- -----------------
                   **             **                **                **
                   **             **                **                **
                   **             **                **                **
                   **             **                **                **
         ------------------ ----------------- ---------------- -----------------

---------------
The "**" marks the location of information that has been omitted and filed
separately with the Securities and Exchange Commission pursuant to a request for
confidential treatment.

<PAGE>

EXHIBIT 14.8

                         ALTERNATIVE DISPUTE RESOLUTION

         The parties recognize that bona fide disputes as to certain matters may
arise from time to time during the term of this Agreement that relate to either
party's rights and/or obligations. To have such a dispute resolved by this
Alternative Dispute Resolution (ADR) provision, a party first must send written
notice of the dispute to the other party for attempted resolution by good faith
negotiations between their respective officers (or their equivalents) within
twenty-eight (28) days after such notice is received (all references to "days"
in this Exhibit 14.8 are to calendar days).

         If the matter has not been resolved within twenty-eight (28) days of
the notice of dispute, either party (the "Notifying Party") may notify the other
(the "Receiving Party") in writing that it intends to initiate an ADR
proceedings as provided herein to resolve the dispute ("Written Notice"). If the
Receiving Party agrees to ADR proceedings, either party may initiate an ADR
proceeding as provided herein. The parties shall have the right to be
represented by counsel in such a proceeding.

         1.       To begin an ADR proceeding, a party shall provide written
                  notice to the other party of the issues to be resolved by ADR,
                  including the specific provisions of the Agreement in issue.
                  Within fourteen (14) days after its receipt of such notice,
                  the other party may, by written notice to the party initiating
                  the ADR, add additional issues to be resolved within the same
                  ADR.

         2.       Within twenty-one (21) days following receipt of the original
                  ADR notice, the parties shall select a mutually acceptable
                  neutral to preside in the resolution of any disputes in this
                  ADR proceeding. If the parties are unable to agree on a
                  mutually acceptable neutral within such period, either party
                  may request the President of the CPR Institute for Dispute
                  Resolution (CPR), 366 Madison Avenue, 14th Floor, New York,
                  New York 10017, to select a neutral pursuant to the following
                  procedures:

                  (a)      The CPR shall submit to the parties a list of not
                           less than five (5) candidates within fourteen (14)
                           days after receipt of the request, along with a
                           Curriculum Vitae for each candidate. No candidate
                           shall be an employee, director, or shareholder of
                           either party or any of their subsidiaries or
                           affiliates.

                  (b)      Such list shall include a statement of disclosure by
                           each candidate of any circumstances likely to affect
                           his or her impartiality.

                  (c)      Each party shall number the candidates in order of
                           preference (with the number one (1) signifying the
                           greatest preference) and shall deliver the list to
                           the CPR within seven (7) days following receipt of
                           the list of candidates. If a party believes a
                           conflict of interest exists regarding any of the
                           candidates, that party shall provide a written
                           explanation of the conflict to the CPR along with its
                           list showing its order of preference for the
                           candidates. Any party failing to return a list of
                           preferences on time shall be deemed to have no order
                           of preference.

<PAGE>

                  (d)      If the parties collectively have identified fewer
                           than three (3) candidates deemed to have conflicts,
                           the CPR immediately shall designate as the neutral
                           the candidate for whom the parties collectively have
                           indicated the greatest preference, excluding any
                           candidate deemed by a party to have conflicts. If a
                           tie should result between two candidates, the CPR may
                           designate either candidate. If the parties
                           collectively have identified three (3) or more
                           candidates deemed to have conflicts, the CPR shall
                           review the explanations regarding conflicts and, in
                           its sole discretion, may either (i) immediately
                           designate as the neutral the candidate for whom the
                           parties collectively have indicated the greatest
                           preference, or (ii) issue a new list of not less than
                           five (5) candidates, in which case the procedures set
                           forth in subparagraphs 2(a) - 2(d) shall be repeated.

         3.       No earlier than twenty-eight (28) days or later than fifty-six
                  (56) days after selection, the neutral shall hold a hearing to
                  resolve each of the issues identified by the parties. The ADR
                  proceeding shall take place at a location agreed upon by the
                  parties. If the parties cannot agree, the neutral shall
                  designate a location other than the principal place of
                  business of either party or any of their subsidiaries or
                  affiliates.

         4.       At least seven (7) days prior to the hearing, each party shall
                  submit the following to the other party and the neutral:

                  (a)      a copy of all exhibits on which such party intends to
                           rely in any oral or written presentation to the
                           neutral;

                  (b)      a list of any witnesses such party intends to call at
                           the hearing, and a short summary of the anticipated
                           testimony of each witness;

                  (c)      a proposed ruling on each issue to be resolved,
                           together with a request for a specific damage award
                           or other remedy for each issue. The proposed rulings
                           and remedies shall not contain any recitation of the
                           facts or any legal arguments and shall not exceed one
                           (1) page per issue; and

                  (d)      a brief in support of such party's proposed rulings
                           and remedies, provided that the brief shall not
                           exceed twenty (20) pages. This page limitation shall
                           apply regardless of the number of issues raised in
                           the ADR proceeding.

         Except as expressly set forth in subparagraphs 4(a) - 4(d), no
         discovery shall be required or permitted by any means, including
         depositions, interrogatories, requests for admissions, or production of
         documents.

<PAGE>

         5.       The hearing shall be conducted on two (2) consecutive days and
                  shall be governed by the following rules:

                  (a)      Each party shall be entitled to five (5) hours of
                           hearing time to present its case. The neutral shall
                           determine whether each party has had the five (5)
                           hours to which it is entitled.

                  (b)      Each party shall be entitled, but not required, to
                           make an opening statement, to present regular and
                           rebuttal testimony, documents or other evidence, to
                           cross-examine witnesses, and to make a closing
                           argument. Cross-examination of witnesses shall occur
                           immediately after their direct testimony, and
                           cross-examination time shall be charged against the
                           party conducting the cross-examination.

                  (c)      The party initiating the ADR shall begin the hearing
                           and, if it chooses to make an opening statement,
                           shall address not only issues it raised but also any
                           issues raised by the responding party. The responding
                           party, if it chooses to make an opening statement,
                           also shall address all issues raised in the ADR.
                           Thereafter, the presentation of regular and rebuttal
                           testimony and documents, other evidence, and closing
                           arguments shall proceed in the same sequence.

                  (d)      Except when testifying, witnesses shall be excluded
                           from the hearing until closing arguments.

                  (e)      Settlement negotiations, including any statements
                           made therein, shall not be admissible under any
                           circumstances. Affidavits prepared for purposes of
                           the ADR hearing also shall not be admissible. As to
                           all other matters, the neutral shall have sole
                           discretion regarding the admissibility of any
                           evidence.

         6.       Within seven (7) days following completion of the hearing,
                  each party may submit to the other party and the neutral a
                  post-hearing brief in support of its proposed rulings and
                  remedies, provided that such brief shall not contain or
                  discuss any new evidence and shall not exceed ten (10) pages.
                  This page limitation shall apply regardless of the number of
                  issues raised in the ADR proceeding.

         7.       The neutral shall rule on each disputed issue within fourteen
                  (14) days following completion of the hearing. Such ruling
                  shall adopt in its entirety the proposed ruling and remedy of
                  one of the parties on each disputed issue but may adopt one
                  party's proposed rulings and remedies on some issues and the
                  other party's proposed rulings and remedies on other issues.
                  The neutral shall not issue any written opinion or otherwise
                  explain the basis of the ruling.

         8.       The neutral shall be paid a reasonable fee plus expenses.
                  These fees and expenses, along with the reasonable legal fees
                  and expenses of the prevailing party (including all expert
                  witness fees and expenses), the fees and expenses of a court
                  reporter, and any expenses for a hearing room, shall be paid
                  as follows:

<PAGE>

                  (a)      If the neutral rules in favor of one party on all
                           disputed issues in the ADR, the losing party shall
                           pay 100% of such fees and expenses.

                  (b)      If the neutral rules in favor of one party on some
                           issues and the other party on other issues, the
                           neutral shall issue with the rulings a written
                           determination as to how such fees and expenses shall
                           be allocated between the parties. The neutral shall
                           allocate fees and expenses in a way that bears a
                           reasonable relationship to the outcome of the ADR,
                           with the party prevailing on more issues, or on
                           issues of greater value or gravity, recovering a
                           relatively larger share of its legal fees and
                           expenses.

         9.       The rulings of the neutral and the allocation of fees and
                  expenses shall be binding, non-reviewable, and non-appealable
                  (except in the case of fraud or bad faith on the part of the
                  neutral), and may be entered as a final judgment in any court
                  having jurisdiction.

         10.      Except as provided in paragraph 9 or as required by law, the
                  existence of the dispute, any settlement negotiations, the ADR
                  hearing, any submissions (including exhibits, testimony,
                  proposed rulings, and briefs), and the rulings shall be deemed
                  Confidential Information (except for information contained in
                  exhibits or testimony that is already public or later becomes
                  public through no fault of the parties or that is lawfully
                  disclosed to a party through an independent third party). The
                  neutral shall have the authority to impose sanctions for
                  unauthorized disclosure of Confidential Information.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00055-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00055-of-00352.parquet"}]]